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Abstract
Background: It is expected that prolonged circulation of anticancer drugs will increase their
anticancer activity while decreasing their toxic side effects. The purpose of this study was to
prepare 5-fluorouracil (5-FU) loaded block copolymers, with poly(γ-benzyl-L-glutamate) (PBLG) as
the hydrophobic block and poly(ethylene glycol) (PEG) as the hydrophilic block, and then examine
the 5-FU release characteristics, pharmacokinetics, and anticancer effects of this novel compound.
Methods: 5-FU loaded PEG-PBLG (5-FU/PEG-PBLG) nanoparticles were prepared by dialysis and
then scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were used
to observe the shape and size of the nanoparticles, and ultraviolet spectrophotometry was used to
evaluate the 5-FU in vitro release characteristics. The pharmacokinetic parameters of 5-FU/PEG-
PBLG nanoparticles in rabbit plasma were determined by measuring the 5-FUby high-performance
liquid chromatography (HPLC). To study in vivo effects, LoVo cells (human colon cancer cell line)
or Tca8113 cells (human oral squamous cell carcinoma cell line) were implanted in BALB/c nude
mice that were subsequently treated with 5-FU or 5-FU/PEG-PBLG nanospheres.
Results: 5-FU/PEG-PBLG nanoparticles had a core-shell spherical structure with a diameter of 200
nm and a shell thickness of 30 nm. The drug loading capacity was 27.1% and the drug encapsulation
was 61.5%. Compared with 5-FU, 5-FU/PEG-PBLG nanoparticles had a longer elimination half-life
(t1/2, 33.3 h vs. 5 min), lower peak concentration (C, 4563.5 μg/L vs. 17047.3 μg/L), and greater
distribution volume (VD, 0.114 L vs. 0.069 L). Compared with a blank control, LoVo cell xenografts
and Tca8113 cell xenografts treated with 5-FU or 5-FU/PEG-PBLG nanoparticles grew slower and
had prolonged tumor doubling times. 5-FU/PEG-PBLG nanoparticles showed greater inhibition of
tumor growth than 5-FU (p < 0.01). In the PEG-PBLG nanoparticle control group, there was no
tumor inhibition (p > 0.05).
Conclusion: In our model system, 5-FU/PEG-PBLG nanoparticles changed the pharmacokinetic
behavior of 5-FU, thus increasing its anticancer activity. 5-Fluorouracil loaded nanoparticles have
potential as a novel anticancer drug that may have useful clinical applications.
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Background
A large body of cancer research has been devoted to the
development of targeted anti-neoplastic drugs that are
selectively taken up by tumor tissues. Toward this end,
researchers have recently developed anti-cancer drugs that
are incorporated into polymeric micelles, surface-modi-
fied particles, liposomes, or nanoparticles [1-4]. However,
there are problems with this general approach, including
limited biodistribution, toxic side effects, rapid clearance
by the reticuloendothelial system (RES), and limited dis-
tribution in the circulation.
Hydrophilic-hydrophobic diblock copolymers have great
potential as vehicles for the delivery of anticancer drugs
[5-9]. A hydrophobic block forms the inner core, which
acts as a drug reservoir, and a hydrophilic block forms the
hydrated outer shell, which impedes uptake by the RES
[10,11]. The advantages of these copolymers includes sol-
ubilization of hydrophobic drugs, sustained release and
selective targeting of drugs, and reduced drug interaction
with the RES [10,11]. Nanoparticles prepared from
poly(γ-benzyl-L-glutamate) (PBLG) and poly(ethylene
glycol) (PEG) are a hydrophilic-hydrophobic diblock
copolymer that have all of these characteristics [5-9].
PBLG, the hydrophobic moiety, is biodegradable and acts
as a drug incorporation site [12]. PEG, the hydrophilic
moiety, is a non-toxic, non-immunogenic hydrophilic
polymer that prevents interactions with cells and proteins
[13].
5-Fluorouracil (5-FU), a pyrimidine analogue that inter-
feres with thymidylate synthesis, has a broad spectrum of
activity against solid tumors. However, 5-FU has limita-
tions that include a short biological half-life due to rapid
metabolism, incomplete and non-uniform oral absorp-
tion due to metabolism by dihydropyrimidine dehydro-
genase [14-17], toxic side effects on bone marrow and the
gastrointestinal tract, and non-selective action against
healthy cells [18].
In order to prolong the circulation time of 5-FU and
increase its efficacy, numerous researchers have attempted
to modify its delivery by use of polymer conjugates or by
incorporation of 5-FU into particulate carriers [19-23].
The ultimate aim of these strategies is to reduce 5-FU asso-
ciated side effects and thereby improve its therapeutic
index [19-23]. In this study, we used a diafiltration
method to prepare 5-FU-loaded PEG-PBLG (5-FU/PEG-
PBLG) nanoparticles and evaluate their physical charac-
teristics, in vitro release behavior, and anti-tumor activity.
Methods
Preparation of PEG-PBLG
PEG-PBLG block copolymers (MW, 1.12 × 104) were pre-
pared by polymerization of γ-benzyl-L-glutamate N-car-
boxyanhydride (γ-BLG NCA) initiated with mono amine-
terminated PEG in a methylene dichloride solution, as
described previously [24]. Briefly, we prepared the
monoamino-terminated poly(ethylene glycol) (MeO-
PEG-NH2) by the use of toluene sulfonate esterification
with MeO-PEG-OH. The production rate of this process
was 51.9 % and the transformation rate was 68.2%. The γ-
benzyl-L-glutamate was obtained by reaction of glutamic
acid with benzyl alcohol at 120°C for 5 h under 60% sul-
furic acid (activator), and then reacted with triphosgene to
obtain the monomer of γ-benzyl-L-glutamate N-carboxyl
anhydride (BLG-NCA). The process production rate was
53.2%. The amphiphilic block copolymer was the pre-
pared by anionic polymerization of BLG-NCA initiated by
MeO-PEG-NH2 with a 50/1 molar ratio of monomer/ini-
tiator. The resulting molecular weight was 1.12 × 104. IR
and 1H-NMR demonstrated that MeO-PEG-NH2  was
polymerized with BLG-NCA to form PEG-PBLG.
Drug and Chemicals
5-FU was purchased from Sigma (USA). Other chemicals
were of laboratory grade purity.
Cell Culture
Human colon cancer cells (LoVo cell line) and human
oral squamous carcinoma cells (Tca8113 cell line) were
grown in RPMI 1640 medium (GIBCO) with 10% fetal
calf serum (GIBCO), 100 units/ml penicillin G, and 100
μg/ml streptomycin at 37°C in 5% CO2.
Animals
New Zealand rabbits (2–3 kg) and BALB/c nude mice (6–
8 weeks old, 20–30 g) were purchased from the animal
center at Sun Yat-sen University (Guangzhou, China). All
animal experiments were performed with permission of
the Animal Ethical Commission of Sun Yat-sen Univer-
sity.
Preparation and identification of 5-FU/PEG-PBLG 
nanoparticles
5-FU/PEG-PBLG nanoparticles were prepared by a diafil-
tration method. Briefly, we dissolved PEG-PBLG diblock
copolymers and 5-FU (1:1 w/w) in dimethylformamide
(DMF) and dialyzed the solution (with a molecular
weight cut-off of 3500 g/mol; Spectrum Medical Indus-
tries, Inc., Houston, TX) in double-distilled water for 24 h.
The solution inside the dialysis bags was collected and
then centrifuged (2000 rpm/min; 10 min). The superna-
tant (nanoparticles) was filtered with a 0.45 μm filter. The
samples were then freeze-dried for subsequent use. A 640
UV spectrophotometer (Bechman) was used to identify
the 5-FU/PEG-PBLG nanoparticles by scanning from 200
nm to 400 nm.BMC Cancer 2008, 8:103 http://www.biomedcentral.com/1471-2407/8/103
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Morphology of PEG-PBLG nanoparticles
A scanning electron microscope (HITACH-600, Japan)
and a transmission electron microscope (PHILIPS, Hol-
land) were used to examine particle morphology. For
SEM, PEG-PBLG samples were filtered with a 0.45 μm
sieve and dropped onto a slide. The prepared samples
were dried at room temperature for several days and then
gilded. The final concentration of the gilded samples was
0.2 mg/ml. For TEM, one drop of the PEG-PBLG sample
was added to a copper supported mesh membrane and
the excess solution removed with filter paper. Then, 1%
phosphotungstic acid was added to the mesh membrane.
Excess solution was removed after 1 minute and the sam-
ple dried at room temperature. The concentration of pre-
pared sample was 0.2 mg/ml.
Loading capacity, drug encapsulation, and in vitro release
5-FU/PEG-PBLG nanoparticles were placed into dialysis
bags and the bags were introduced into a DMF solution.
After stirred at 37°C for 3 h dialysed sample was deter-
mined for drug concentration by measuring absorbance at
269 nm. The drug loading capacity and drug encapsula-
tion were calculated by the following formulas:
Drug loading capacity = M5-FU/M5-FU/PEG-PBLG
Drug encapsulation = M5-FU/Mdrug devoted
where M5-FU was the drug content detected in solution
[M5-FU = D5-FU × V, D5-FU = (Asample/Astandard) × Dstandard, D:
concentration, V: volume]; M5-FU/PEG-PBLG was quantity of
5-FU/PEG-PBLG nanoparticles detected in solution; and
Mdrug devoted was the initial quantity of 5-FU.
For in vitro release studies, 5-FU/PEG-PBLG nanoparticles
were placed into dialysis bags and the bags were intro-
duced into PBS at pH 6.86 or pH 9.18. The medium was
stirred at 94 ± 4 beats/min at 37°C. The medium was
replaced with fresh PBS at variable periods of time up to
96 h. We determined the concentration of 5-FU that was
released into the PBS by measuring the absorbance at 269
nm.
Pharmacokinetic studies of 5-FU/PEG-PBLG nanoparticles 
in rabbit plasma
A single dose of 5-FU or 5-FU/PEG-PBLG nanoparticles
(30 mg/kg) was administered to rabbits. Blood samples
were collected from rabbit veins at designated times after
intravenous administration. 5-FU was extracted from
plasma by mixing rabbit plasma with ethyl acetate and
isopropyl alcohol (85/15, v/v). The samples were then
dried with N2 at 37°C and the dehydrated samples were
dissolved in 400 μl of mobile phase dilutent for subse-
quent HPLC.
The concentration of released 5-FU was measured using
reversed-phase HPLC (HP1100 Liquid Chromatogragh,
Agilent). A Hypersil C18 (5 μm, ID 4.6 mm × 300 mm)
analytical column was used with a mobile phase of 0.01
mol/L phosphate buffer (pH 3.0) and an elution rate of
1.0 ml/min at room temperature. Absorbance at 269 nm
was monitored and pharmacokinetic parameters were
determined from the absorbance-time curves. This
method provided complete separation with a correspond-
ing retention time of 7.0 minutes for 5-FU. The standard
calibration curve of 5-FU absorbance with concentration
was y = 3.47x + 0.24 (γ > 0.9998). The lower limit of deter-
mination was 5 μg/L.
In vivo tumor inhibition effect of 5-FU loaded 
nanoparticles
LoVo cells were subcutaneously implanted in the right
flank of BALB/c nude mice. Mice were assigned to one of
4 groups (n = 8) after xenografts were about 5 mm in
diameter: 1) control group (PBS), 2) PEG-PBLG group, 3)
5-FU group, 4) 5-FU/PEG-PBLG nanoparticle (3 mg/kg)
group. For groups 3 and 4, intraperitoneal injections were
administered daily for 7 days. For groups 1 and 2, intra-
peritoneal injections of the same volume of PBS or PEG-
PBLG were administered on the same schedule. The mice
were sacrificed on day 21 and tumor size was measured
(length and width) with a caliperevery 3 days. Tumor
parameters were calculated on day 21 by the following
formulas: Tumor volume = (1/2 × length × width2);
Tumor doubling time = (ln2/K where K = growth rate);
Inhibition rate at day 21 = (1- volume change of experi-
mental group/volume change of control group) × 100%.
For the mice with implanted Tca8113 cells, 5-FU or 5-FU/
PEG-PBLG (3 mg/kg) was injected intraperitoneally every
2 days for 16 days. Mice were sacrificed on day 34.
Statistical analysis
All experiments were performed in triplicate and data are
presented as mean ± SD. The tumor growth inhibitory
effect of drugs was analyzed using one-way analysis of var-
iance. P < 0.05 was considered as statistically significant.
Results and Discussion
Characteristics of 5-FU/PEG-PBLG nanoparticles
Drug-loaded nanoparticles have a diameter ranging from
10 nm to 500 nm and incorporate a drug by conjugation,
physical entrapment, absorption, or by other mecha-
nisms. Nanoparticles can enhance the solubilization of a
hydrophobic drug, protect drug activity, increase drug sta-
bility, improve the drug's therapeutic index, and decrease
adverse side effects [2-9]. Drug-loaded nanoparticles are
widely used for anticancer drugs because of their
enhanced targeting properties [2-9,25]. Previously,
researchers have used copolymers of PEG and PBLG, aBMC Cancer 2008, 8:103 http://www.biomedcentral.com/1471-2407/8/103
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biocompatible and biodegradable macromolecular mate-
rial, as the nanoparticle carrier for a drug [5-9]. In this
study, we prepared 5-FU/PBLG-PEG nanoparticles by a
diafiltration method. Analysis by UV spectrophotometry
(Figure 1) showed that a solution of 5-FU, or a simple
mixture of 5-FU and PBLG-PEG nanoparticles, had high
absorbance at 269 nm. However, the absorbance of 5-FU/
PEG-PBLG nanoparticles at 269 nm had greatly decreased.
This indicates that 5-FU can be loaded into PEG-PBLG
nanoparticles by diafiltration. Based on the decrease in
absorbance at 269 nm, we estimate the drug loading
capacity as 27.1% and the drug encapsulation as 61.5%.
Experiments to determine drug release and pharmacoki-
netics were performed to demonstrate the reliability of the
aforementioned observation. It's also of note that the drug
loading capacity in our study was higher than the 10%
achieved by Nagaich et al. [19] who prepared 5-FU loaded
PEG-polysaccharide nanoparticles. Whether the differ-
ence is due to the PBLG component, which has a steel-like
structure and forms a hydrophobic core, remains to be
determined [26-28].
Like many other polymeric nanoparticles [5-9], the mor-
phology of our 5-FU/PEG-PBLG nanoparticles is spherical
or elliptical, with a core-shell structure, and a smooth sur-
face (Figure 2). The hydrophobic PBLG central core is a
non-gilt grizzly area, about 200 nm in diameter, and the
PEG hydrophilic shell is a gilt white area, approximately
30 nm in thickness (Figure 2A). A representative TEM scan
of the 5-FU/PEG-PBLG nanoparticle is shown in Figure
2B. Previous research has shown that nanoparticles are
not easily phagocytized when the thickness of the PEG
layer is 10 nm for every 100 nm thickness of the micelles.
This indicates that the RES should not take up the 5-FU/
PEG-PBLG nanoparticles examined in this study.
In vitro release of 5-FU loaded nanoparticles
Nanoparticle release occurs by 2 methods: "burst release"
and "sustained release" [29-32]. Burst release is the rapid
release of a drug from the surface of nanoparticles or dif-
fusion from the polymer matrix. This allows the drug to
rapidly reach an effective concentration in the circulation.
Sustained release is the slow release of a drug that is
entrapped within nanoparticles during nanoparticle bio-
UV spectra of 5-FU/PEG-PBLG nanoparticles Figure 1
UV spectra of 5-FU/PEG-PBLG nanoparticles. I: 5-FU; II: 5-FU + PEG-PBLG nanoparticles; III: 5-FU/PEG-PBLG nanopar-
ticles. I and II had high absorbance at 269 nm while the absorbance of III was much lower at 269 nm.BMC Cancer 2008, 8:103 http://www.biomedcentral.com/1471-2407/8/103
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The core-shell structure of 5-FU/PEG-PBLG nanoparticles Figure 2
The core-shell structure of 5-FU/PEG-PBLG nanoparticles. (A) Morphology under SEM (× 80000). SEM showed 
5-FU/PEG-PBLG nanoparticles have a core-shell structure, a spherical or elliptical shape, and a smooth surface. The hydropho-
bic central core is a non-gilt grizzly area, about 200 nm in diameter and the hydrophilic shell is a gilt white area, about 30 nm in 
thickness. (B) Morphology under TEM (× 50000). TEM showed that nanomicelles were round or oval particles of uniform 
size with fuzzy edges.BMC Cancer 2008, 8:103 http://www.biomedcentral.com/1471-2407/8/103
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degradation. This allows the drug to stay at an effective
concentration in the circulation over time. Figure 3 shows
the in vitro 5-FU release profiles from PEG-PBLG nano-
particles at pH 6.86 and pH 9.18. This brackets the normal
pH of human blood (pH ~7.4). The 5-FU release profiles
are composed of burst release and sustained release [33].
The burst release, which resulted in the release of ~30% of
the 5-FU, occurred from 0 to 2 h. The sustained release
occurred from 2 to 96 h and resulted in the release of
~50% of the 5-FU.
Pharmacokinetics characteristic of 5-FU/PEG-PBLG 
nanoparticles in vivo
Clinically, 5-FU can be administered by bolus injection,
which primarily inhibits RNA synthesis, or by continuous
infusion, which primarily inhibits DNA synthesis. Clini-
cal response would be expected to be enhanced if both
methods could be combined [16,17]. The half-life of 5-FU
in vivo is only 5 to 10 min; thus, many studies have
attempted to develop 5-FU preparations with a prolonged
lifetime [21,32].
To study the in vivo characteristics of the 5-FU/PEG-PBLG
nanoparticles, we administered 5-FU or 5-FU/PEG-PBLG
nanoparticles to rabbits at a single dose of 30 mg/kg. The
absolute recovery and relative recovery of 5-FU were 73.5
to 82.6% and 98.6 to 100.8%, respectively. The intra- and
inter-day RSD (relative standard deviation) was less than
10%, justifying this method for study of 5-FU pharmacok-
inetics in rabbits. As Figure 4 shows, 5-FU alone followed
a one-compartment model, but 5-FU/PEG-PBLG nano-
particles followed a multi-compartment model with a
burst release followed by a sustained release. Compared
with 5-FU, 5-FU/PEG-PBLG nanoparticles have a greater
elimination half-life (t1/2), lower peak concentration
(Cmax), greater distribution volume (Tmax), and slightly
lower area under the curve (AUC) (Table 1). This indicates
that when 5-FU is loaded into nanoparticles, the 5-FU has
sustained-release, prolonged half-life, and increased tissue
appetency. It is noteworthy that the pharmacokinetic
characteristics of our 5-FU loaded PEG/PBLG nanoparti-
cles are similar to the 5-FU loaded PEG-polysaccharide
nanoparticles of Nagaich et al. [19].
In vitro release of 5-FU from PEG-PBLG nanoparticles at pH 6.86 and pH 9.18 Figure 3
In vitro release of 5-FU from PEG-PBLG nanoparticles at pH 6.86 and pH 9.18.BMC Cancer 2008, 8:103 http://www.biomedcentral.com/1471-2407/8/103
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Anticancer effect of 5-FU loaded nanoparticles in vivo
5-FU is clinically effective against human colorectal cancer
and oral squamous cell carcinoma [14]. Figures 5A and 5B
show that LoVo cell xenografts (colorectal cancer) and
Tca8113 cell xenografts (oral squamous carcinoma) grew
rapidly in blank and in the PEG-PBLG control groups.
However, 5-FU and 5-FU/PEG-PBLG nanoparticles signif-
icantly inhibited tumor growth. Tumor doubling times
and inhibition rates are presented in Table 2. There were
no differences between the 2 control groups (p > 0.05),
but there were significant differences between the 2
treated groups (p < 0.01). We observed no significant tox-
icity in any group. The more effective anticancer effect of
5-FU/PEG-PBLG nanoparticles (Figure 5, Table 2) may be
due to: 1) the sustained-release, prolonged half-life, and
increased apparent volume of distribution of 5-FU/PEG-
PBLG nanoparticles and/or 2) the neovascularization and
higher permeability of blood vessels present in tumor
cells, making it easier for nanoparticles to enter tumor
cells and thereby increase the anticancer effect of 5-FU.
Conclusion
In this study, we prepared 5-FU loaded PEG-PBLG nano-
particles (5-FU/PEG-PBLG) which exhibited favorable
pharmacokinetic characteristics, including sustained drug
release, prolonged drug half-life, and increased tissue
appetency. In vivo, 5-FU/PEG-PBLG nanoparticles had
good anti-tumor activity against colon cancer xenografts
and oral squamous cell carcinoma xenografts. Taken
together, our results indicate that a PEG-PBLG nanoparti-
cle delivery system for 5-FU may be able to effectively
Mean plasma concentration of 5-FU following a single i.v. administration of 5-FU or 5-FU/PEG-PBLG nanoparticles at 30 mg/kg Figure 4
Mean plasma concentration of 5-FU following a single i.v. administration of 5-FU or 5-FU/PEG-PBLG nanopar-
ticles at 30 mg/kg. The arrow depicts sustained release.
Table 1: In vivo pharmacokinetic parameters of 5-FU and 5-FU/PEG-PBLG nanoparticles
t1/2(h) Cmax (μg/L) Tmax(h) Vd(L) AUC(μg · h/L)
5-FU 0.088 17047.3 0 0.069 6263.7
5-FU/PEG-PBLG 33.3 4563.5 1.25 0.114 5794.7
t1/2, elimination half-life; Cmax, peak concentration; Tmax, peak time; AUC, area under the concentration-time curve; Vd, distribution volume.BMC Cancer 2008, 8:103 http://www.biomedcentral.com/1471-2407/8/103
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reduce adverse side effects of 5-FU therapy and improve
the therapeutic index of 5-FU.
List of abbreviations
5-FU, 5-fluorouracil; PBLG, poly(γ-benzyl L-glutamate);
PEG, poly(ethylene glycol); SEM, scanning electron
microscopy; HPLC, high-performance liquid chromatog-
raphy; RES, reticuloendothelial system, DMF, N,N-
dimethylformamide; t1/2, elimination half-life; Cmax, peak
concentration; Tmax, peak time; AUC, area under the con-
centration-time curve; VD, distribution volume; TDT,
tumor doubling time; IR, inhibition rate; TV, tumor vol-
ume at day 21 for LoVo cell xenografts or day 34 for Tca
8113 cell xenografts.
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Tumor growth of LoVo cell xenografts (A) and Tca8113 cell xenografts (B) after treatment with 5-FU or 5-FU/PEG-PBLG nan- oparticles Figure 5
Tumor growth of LoVo cell xenografts (A) and Tca8113 cell xenografts (B) after treatment with 5-FU or 5-FU/
PEG-PBLG nanoparticles.
Table 2: The anticancer effect of 5-FU/PEG-PBLG nanoparticles
LoVo cell xenografts Tca8113 cell xenografts
TDT (d) IR (%) TV(cm3)T D T  ( d ) I R  ( % ) T V ( c m 3)
Blank control 3.0 0 4.336 ± 0.485 3.5 0 3.888 ± 0.547
PEG-PBLG 2.9 0 4.206 ± 0.308* 3.6 0 3.944 ± 0.179*
5-FU 4.08 62.2% 1.637 ± 0.330# 4.6 65.4% 1.346 ± 0.142#
5-FU/PEG-PBLG 4.50 77.1% 0.993 ± 0.122#§ 5.3 89.6% 0.405 ± 0.174#§
TDT, tumor doubling time; IR, inhibition rate; TV, tumor volume at day 21 for LoVo cell xenografts and at day 34 for Tca 8113 cell xenografts.
*compared with blank control, p > 0.05.
#compared with blank control, p < 0.01,
§compared with 5-FU, p < 0.01.BMC Cancer 2008, 8:103 http://www.biomedcentral.com/1471-2407/8/103
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